3 terminated, 1 active not recruiting, 1 approved for marketing, 1 available. 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Terminated 2 |
Follow narsoplimab: new trials by email Literature Review of narsoplimab trials Research Report on narsoplimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA Biological: narsoplimab - Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation | Phase 2 | Recruiting | Omeros Corporation | 18 | 2023-05-01 | 2025-03-25 |
| I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Remdesivir, Imatinib Mesylate, Dexamethasone - COVID-19 | Phase 2 | Active not recruiting | QuantumLeap Healthcare Collaborative | 1500 | 2020-07-31 | 2026-03-16 |
| Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome OMS721 (narsoplimab) - Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome | Phase 3 | Terminated | Omeros Corporation | 6 | 2018-05-02 | 2025-12-10 |
| Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy OMS721, Vehicle (D5W or saline) - IgA Nephropathy | Phase 3 | Terminated | Omeros Corporation | 360 | 2018-04-05 | 2025-12-09 |
| Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 OMS721 (narsoplimab) - IgAN, LN | Phase 2 | Terminated | Omeros Corporation | 31 | 2016-03-10 | 2026-03-30 |
| Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies OMS721 - Thrombotic Microangiopathies | Phase 2 | Completed | Omeros Corporation | 58 | 2014-11-02 | 2024-08-28 |
| Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab Narsoplimab - Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA) | Approved for marketing | Omeros Corporation | 2026-03-05 | |||
| OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy OMS721 - Thrombotic Microangiopathy | Available | Michal Nowicki | 2015-04-15 |
Thrombotic Microangiopathies (4) · Atypical Hemolytic Uremic Syndrome (3) · Glomerulonephritis, IGA (2) · COVID-19 (1) · Disease (1) · Glomerulonephritis, Membranous (1) · Lupus Nephritis (1) · Proteinuria (1) · Renal Insufficiency, Chronic (1) · Respiratory Distress Syndrome (1) · Respiratory Insufficiency (1)
Omeros Corporation (6) · Michal Nowicki (1) · QuantumLeap Healthcare Collaborative (1)
United States (6) · Lithuania (3) · Poland (3) · Taiwan (3) · Belgium (2) · Bulgaria (2) · Germany (2) · Hong Kong (2) · Italy (2) · Singapore (2) · Spain (2) · Thailand (2) · Argentina (1) · Australia (1) · Canada (1)
Derek W Russell, MD (1) · Kathleen D Liu, MD (1) · Laura Esserman, MD (1) · Michal Nowicki, MD, PhD (1)
PMID 33783815, PMID 34473343, PMID 35439028, PMID 35675911, PMID 36883141, PMID 37772889, PMID 39592213, PMID 40462830, PMID 42799508
2014 (1)